These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3978249)

  • 41. Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era.
    Teruel JL; Aguilera A; Marcen R; Navarro Antolin J; Garcia Otero G; Ortuño J
    Scand J Urol Nephrol; 1996 Oct; 30(5):403-8. PubMed ID: 8936631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tamoxifen in the treatment of male breast carcinoma.
    Ribeiro GG
    Clin Radiol; 1983 Nov; 34(6):625-8. PubMed ID: 6673881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre.
    Mauriac L; Durand M; Chauvergne J; Bonichon F; Avril A; Mage P; Dilhuydy MH; Le Treut A; Wafflart J; Marée D
    Breast Cancer Res Treat; 1988 May; 11(2):179-86. PubMed ID: 3042053
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy.
    Fisher B; Redmond CK; Wickerham DL; Rockette HE; Brown A; Allegra J; Bowman D; Plotkin D; Wolter J
    Breast Cancer Res Treat; 1983; 3(4):355-64. PubMed ID: 6365208
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen.
    Mouridsen HT; Rose C; Engelsman E; Sylvester R; Rotmensz N
    Eur J Cancer Clin Oncol; 1985 Mar; 21(3):291-9. PubMed ID: 3891357
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of danazol on tumour control and weight loss in patients on tamoxifen therapy for advanced breast cancer: a randomised double-blind placebo controlled trial.
    Bishop JF; Smith JG; Jeal PN; Murray R; Drummond RM; Pitt P; Olver IN; Bhowal AK
    Eur J Cancer; 1993; 29A(6):814-8. PubMed ID: 8484970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of nandrolone decanoate on VO2max, running economy, and endurance in rats.
    Georgieva KN; Boyadjiev NP
    Med Sci Sports Exerc; 2004 Aug; 36(8):1336-41. PubMed ID: 15292741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Steroid hormone receptors and cellular proliferative activity following the short-term use of tamoxifen and chlorotrianisene in breast cancer].
    Vyshinskaia GV; Murav'eva NI; Shelsputina ZF; Kuz'mina ZV; Nikolaeva TG
    Eksp Onkol; 1985; 7(5):66-8. PubMed ID: 4065023
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).
    Hartgens F; Rietjens G; Keizer HA; Kuipers H; Wolffenbuttel BH
    Br J Sports Med; 2004 Jun; 38(3):253-9. PubMed ID: 15155420
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients.
    Barton Pai A; Chretien C; Lau AH
    Clin Nephrol; 2002 Jul; 58(1):38-46. PubMed ID: 12141405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials.
    Kuss JT; Muss HB; Hoen H; Case LD
    Breast Cancer Res Treat; 1997 Feb; 42(3):265-74. PubMed ID: 9065610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclophosphamide and nandrolone decanoate in the treatment of advanced carcinoma of the breast--results of a comparative controlled trial of the agents used singly and in combination.
    Cole MP; Todd ID; Wilkinson PM
    Br J Cancer; 1973 May; 27(5):396-9. PubMed ID: 4576562
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Present status of endocrine therapy of breast cancer: a surgeon's view].
    Nomura Y
    Gan To Kagaku Ryoho; 1984 May; 11(5):981-8. PubMed ID: 6426405
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systemic therapy of breast cancer--1985.
    Vogel CL
    Semin Oncol Nurs; 1985 Aug; 1(3):189-94. PubMed ID: 3849050
    [No Abstract]   [Full Text] [Related]  

  • 55. Nandrolone decanoate treatment of post-menopausal osteoporosis for 2 years and effects of withdrawal.
    Hassager C; Riis BJ; Pødenphant J; Christiansen C
    Maturitas; 1989 Dec; 11(4):305-17. PubMed ID: 2693918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of nandrolone decanoate on the repopulation of the thymus after total body irradiation of mice.
    Plum J; Huys J; De Scheerder Y; Dhont E; De Smedt M
    Immunopharmacology; 1982 Oct; 5(1):19-30. PubMed ID: 6752097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.
    Boccardo F; Canobbio L; Resasco M; Decensi AU; Pastorino G; Brema F
    J Cancer Res Clin Oncol; 1990; 116(5):503-6. PubMed ID: 2229142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nandrolone decanoate for men with osteoporosis.
    Hamdy RC; Moore SW; Whalen KE; Landy C
    Am J Ther; 1998 Mar; 5(2):89-95. PubMed ID: 10099043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant chemo- and endocrine therapy alone or in combination in premenopausal patients (GABG Trial 1).
    Kaufmann M; Jonat W; Abel U
    Recent Results Cancer Res; 1989; 115():118-25. PubMed ID: 2696024
    [No Abstract]   [Full Text] [Related]  

  • 60. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
    Esteva FJ; Glaspy J; Baidas S; Laufman L; Hutchins L; Dickler M; Tripathy D; Cohen R; DeMichele A; Yocum RC; Osborne CK; Hayes DF; Hortobagyi GN; Winer E; Demetri GD
    J Clin Oncol; 2003 Mar; 21(6):999-1006. PubMed ID: 12637463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.